Literature DB >> 1660837

Efficient selection for high-expression transfectants with a novel eukaryotic vector.

H Niwa1, K Yamamura, J Miyazaki.   

Abstract

We have developed a new expression vector which allows efficient selection for transfectants that express foreign genes at high levels. The vector is composed of a ubiquitously strong promoter based on the beta-actin promoter, a 69% subregion of the bovine papilloma virus genome, and a mutant neomycin phosphotransferase II-encoding gene driven by a weak promoter, which confers only marginal resistance to G418. Thus, high concentrations of G418 (approx. 800 micrograms/ml) effectively select for transfectants containing a high vector copy number (greater than 300). We tested this system by producing human interleukin-2 (IL-2) in L cells and Chinese hamster ovary (CHO) cells, and the results showed that high concentrations of G418 efficiently yielded L cell and CHO cell transfectants stably producing IL-2 at levels comparable with those previously attained using gene amplification. The vector sequences were found to have integrated into the host chromosome, and were stably maintained in the transfectants for several months.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660837     DOI: 10.1016/0378-1119(91)90434-d

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  1832 in total

1.  Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Authors:  N Matsumura; T Yamazaki; Y Ihara
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Plasmid-driven formation of influenza virus-like particles.

Authors:  G Neumann; T Watanabe; Y Kawaoka
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation.

Authors:  S Matsuda; F Shibasaki; K Takehana; H Mori; E Nishida; S Koyasu
Journal:  EMBO Rep       Date:  2000-11       Impact factor: 8.807

4.  Efficient gene activation in cultured mammalian cells mediated by FLP recombinase-expressing recombinant adenovirus.

Authors:  M Nakano; K Odaka; M Ishimura; S Kondo; N Tachikawa; J Chiba; Y Kanegae; I Saito
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

5.  Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration.

Authors:  K Namikawa; M Honma; K Abe; M Takeda; K Mansur; T Obata; A Miwa; H Okado; H Kiyama
Journal:  J Neurosci       Date:  2000-04-15       Impact factor: 6.167

6.  SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase.

Authors:  A Orian; H Gonen; B Bercovich; I Fajerman; E Eytan; A Israël; F Mercurio; K Iwai; A L Schwartz; A Ciechanover
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

7.  Prostaglandin D synthase gene is involved in the regulation of non-rapid eye movement sleep.

Authors:  E Pinzar; Y Kanaoka; T Inui; N Eguchi; Y Urade; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

8.  Gi-mediated translocation of GLUT4 is independent of p85/p110alpha and p110gamma phosphoinositide 3-kinases but might involve the activation of Akt kinase.

Authors:  L Wang; H Hayashi; K Kishi; L Huang; A Hagi; K Tamaoka; P T Hawkins; Y Ebina
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

9.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

Authors:  A J Pierce; R D Johnson; L H Thompson; M Jasin
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

10.  Sequential requirements of the N-terminal palmitoylation site and SH2 domain of Src family kinases in the initiation and progression of FcepsilonRI signaling.

Authors:  Z i Honda; T Suzuki; H Kono; M Okada; T Yamamoto; C Ra; Y Morita; K Yamamoto
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.